Your browser doesn't support javascript.
loading
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.
Eng, Christina H; Wang, Zuncai; Tkach, Diane; Toral-Barza, Lourdes; Ugwonali, Savuth; Liu, Shanming; Fitzgerald, Stephanie L; George, Elizabeth; Frias, Elizabeth; Cochran, Nadire; De Jesus, Rowena; McAllister, Gregory; Hoffman, Gregory R; Bray, Kevin; Lemon, LuAnna; Lucas, Judy; Fantin, Valeria R; Abraham, Robert T; Murphy, Leon O; Nyfeler, Beat.
Afiliación
  • Eng CH; Oncology Research Unit, Pfizer, Pearl River, NY 10965; christina.eng@pfizer.com beat.nyfeler@novartis.com.
  • Wang Z; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • Tkach D; Oncology Research Unit, Pfizer, Pearl River, NY 10965;
  • Toral-Barza L; Oncology Research Unit, Pfizer, Pearl River, NY 10965;
  • Ugwonali S; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • Liu S; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • Fitzgerald SL; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • George E; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • Frias E; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • Cochran N; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • De Jesus R; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • McAllister G; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • Hoffman GR; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • Bray K; Oncology Research Unit, Pfizer, Pearl River, NY 10965;
  • Lemon L; Oncology Research Unit, Pfizer, Pearl River, NY 10965;
  • Lucas J; Oncology Research Unit, Pfizer, Pearl River, NY 10965;
  • Fantin VR; Oncology Research Unit, Pfizer, San Diego, CA 92121;
  • Abraham RT; Oncology Research Unit, Pfizer, San Diego, CA 92121;
  • Murphy LO; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA 02139;
  • Nyfeler B; Department of Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland christina.eng@pfizer.com beat.nyfeler@novartis.com.
Proc Natl Acad Sci U S A ; 113(1): 182-7, 2016 Jan 05.
Article en En | MEDLINE | ID: mdl-26677873
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Autofagia / Transformación Celular Neoplásica / Cloroquina / Proteínas Proto-Oncogénicas p21(ras) / Resistencia a Antineoplásicos / Antineoplásicos Límite: Humans Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Autofagia / Transformación Celular Neoplásica / Cloroquina / Proteínas Proto-Oncogénicas p21(ras) / Resistencia a Antineoplásicos / Antineoplásicos Límite: Humans Idioma: En Año: 2016 Tipo del documento: Article